These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Di Lorenzo G; De Placido S Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343 [TBL] [Abstract][Full Text] [Related]
5. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Berry W; Eisenberger M Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869 [TBL] [Abstract][Full Text] [Related]
6. New strategies for the medical treatment of prostate cancer. Isaacs JT BJU Int; 2005 Dec; 96 Suppl 2():35-40. PubMed ID: 16359437 [TBL] [Abstract][Full Text] [Related]
7. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528 [TBL] [Abstract][Full Text] [Related]
8. Novel targets and approaches in advanced prostate cancer. Hadaschik BA; Sowery RD; Gleave ME Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516 [TBL] [Abstract][Full Text] [Related]
9. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Lin AM; Ryan CJ; Small EJ Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610 [TBL] [Abstract][Full Text] [Related]
10. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer? Odrazka K; Vaculikova M; Dolezel M; Petera J; Moravek P; Prosvic P; Zoul Z; Vosmik M; Dolezal J; Simakova E Oncol Rep; 2005 Oct; 14(4):1077-81. PubMed ID: 16142375 [TBL] [Abstract][Full Text] [Related]
11. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688 [TBL] [Abstract][Full Text] [Related]
13. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients. Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249 [TBL] [Abstract][Full Text] [Related]
14. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Sava T; Basso U; Porcaro A; Cetto GL Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438 [TBL] [Abstract][Full Text] [Related]
15. Management of the spectrum of hormone refractory prostate cancer. Clarke NW Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118 [TBL] [Abstract][Full Text] [Related]
16. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Oh WK; Tay MH; Huang J Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531 [TBL] [Abstract][Full Text] [Related]
17. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920 [TBL] [Abstract][Full Text] [Related]